U.S. FDA approves Acer Therapeutics' genetic disorder drug
23/12/2022 19:30
Dec 23 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Acer Therapeutics Inc's ACER.O drug for treating patients with a type of genetic disorder called urea cycle disorders, according to the health regulator's website. (Reporting by Raghav Mahobe in Bengaluru; Editing by Anil D'Silva) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31